Kevin S. Boyle, Sr
2021
In 2021, Kevin S. Boyle, Sr earned a total compensation of $4.6M as Chief Executive Officer at ZIOPHARM Oncology.
Compensation breakdown
| Bonus | $147,500 |
|---|---|
| Option Awards | $2,790,638 |
| Salary | $200,000 |
| Stock Awards | $1,435,000 |
| Other | $315 |
| Total | $4,573,753 |
Boyle received $2.8M in option awards, accounting for 61% of the total pay in 2021.
Boyle also received $147.5K in bonus, $200K in salary, $1.4M in stock awards and $315 in other compensation.
Rankings
In 2021, Kevin S. Boyle, Sr's compensation ranked 2,891st out of 12,406 executives tracked by ExecPay. In other words, Boyle earned more than 76.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,891 out of 12,406 | 77th |
Division Manufacturing | 1,150 out of 5,492 | 79th |
Major group Chemicals And Allied Products | 456 out of 2,368 | 81st |
Industry group Drugs | 400 out of 2,089 | 81st |
Industry Pharmaceutical Preparations | 268 out of 1,536 | 83rd |
Source: SEC filing on April 25, 2023.